{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:10:24Z","timestamp":1793992224534,"version":"4.8.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,1,5]]},"DOI":"10.1001\/jama.2020.23370","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T11:12:47Z","timestamp":1607598767000},"page":"50","source":"Crossref","is-referenced-by-count":213,"title":["Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment"],"prefix":"10.1001","volume":"325","author":[{"given":"Xi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Sen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Lianjiang People\u2019s Hospital, Lianjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Guangzhou First People Hospital, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rou-Jun","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Integrated Therapy in Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Li","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, General Hospital of PLA Guangzhou Military Area, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Shenzhen Second People\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Mei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Haikou People\u2019s Hospital, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Qin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Maternal and Child Health Care Hospital of Guangdong Province, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Wen","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jia","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Good Clinical Practice, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Mei","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Foshan First People\u2019s Hospital, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Xia","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Xin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"An","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Good Clinical Practice, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Good Clinical Practice, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hong","family":"Su","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Xi","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui-Kui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Ge","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang-Zan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Yi","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Yu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"South China Breast Cancer Group (SCBCG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"joi200127r1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","article-title":"Pattern of metastatic spread in triple-negative breast cancer.","volume":"115","author":"Dent","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"joi200127r2","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/cncr.v113:10","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"joi200127r3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions.","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"joi200127r4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"issue":"8","key":"joi200127r5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of oral capecitabine (Xeloda(\u201c)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.","volume":"14","author":"Reichardt","year":"2003","journal-title":"Ann Oncol"},{"issue":"11","key":"joi200127r6","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/annonc\/mdq069","article-title":"Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?","volume":"21","author":"Zielinski","year":"2010","journal-title":"Ann Oncol"},{"issue":"16","key":"joi200127r7","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1200\/JCO.19.02474","article-title":"Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III trial.","volume":"38","author":"Li","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"joi200127r8","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy.","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"joi200127r9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2011.35.4639","article-title":"Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.","volume":"30","author":"Joensuu","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"joi200127r10","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/1078-0432.CCR-15-0636","article-title":"Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine.","volume":"21","author":"O\u2019Shaughnessy","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"joi200127r11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01).","volume":"38","author":"Lluch","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"joi200127r12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1078155206069242","article-title":"Management of hand-foot syndrome induced by capecitabine.","volume":"12","author":"Gressett","year":"2006","journal-title":"J Oncol Pharm Pract"},{"issue":"1-2","key":"joi200127r13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3121\/cmr.2008.825","article-title":"Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival.","volume":"7","author":"Onitilo","year":"2009","journal-title":"Clin Med Res"},{"issue":"8","key":"joi200127r14","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9472","key":"joi200127r15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"joi200127r16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/biostatistics\/kxs043","article-title":"Assessing the fit of parametric cure models.","volume":"14","author":"Wileyto","year":"2013","journal-title":"Biostatistics"},{"issue":"32","key":"joi200127r17","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1200\/JCO.2015.61.9510","article-title":"Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM\/2003-10 Study.","volume":"33","author":"Mart\u00edn","year":"2015","journal-title":"J Clin Oncol"},{"key":"joi200127r18","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5483791","article-title":"Metronomic chemotherapy: a systematic review of the literature and clinical experience.","volume":"2019","author":"Simsek","year":"2019","journal-title":"J Oncol"},{"issue":"34","key":"joi200127r19","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","article-title":"Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.","volume":"29","author":"Stockler","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"joi200127r20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2011.06.040","article-title":"Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.","volume":"48","author":"Fedele","year":"2012","journal-title":"Eur J Cancer"},{"key":"joi200127r21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.canlet.2017.01.027","article-title":"Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: a phase II trial.","volume":"400","author":"Montagna","year":"2017","journal-title":"Cancer Lett"},{"issue":"2","key":"joi200127r22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1634\/theoncologist.2014-0379","article-title":"Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM\/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.","volume":"20","author":"Mart\u00edn","year":"2015","journal-title":"Oncologist"},{"issue":"16","key":"joi200127r23","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"20","key":"joi200127r24","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer.","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"joi200127r25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/jcp.2012.37.issue-3","article-title":"Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.","volume":"37","author":"Ma","year":"2012","journal-title":"J Clin Pharm Ther"},{"issue":"13","key":"joi200127r26","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","article-title":"Potential regional differences for the tolerability profiles of fluoropyrimidines.","volume":"26","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"joi200127r27","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2774295\/jama_wang_2020_oi_200127_1650566803.18576.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:00:27Z","timestamp":1650625227000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2774295"}},"subtitle":["The SYSUCC-001 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.23370","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,5]]}}}